Guselkumab in the Treatment of Concomitant Hidradenitis Suppurativa, Psoriasis, and Crohn's Disease.

CONCLUSION: Guselkumab represents a promising therapeutic option for recalcitrant HS patients with inflammatory comorbidities in which IL-23 plays a role.
PMID: 31389737 [PubMed - as supplied by publisher]

Source: Journal of Dermatological Treatment - August 9, 2019 Category: Dermatology Tags: J Dermatolog Treat Source Type: research